Choline-derived TMAO shows similar “direct supplementation” feasibility: in triple-negative breast cancer, either oral TMAO/precursors or intratumoral injection TMAO reshapes the immune microenvironment, strengthens CD8+ effector function, and improves checkpoint inhibitor responses [178]. This evidence concerns the gene CD8A and triple-negative breast carcinoma.